Latest Clinical & Research News
Specialty: Oncology
Adam S. Kibel, MD, and Anna Plym, PhD, of the Division of Urology, and colleagues conducted the most comprehensive study to date on the role of inherited DNA damage response (DDR) genes in aggressive prostate cancer. They report high carrier frequency of DDR gene alterations in lethal cases irrespective of ancestry.
Read More...
Ali Abbas, MD, MPH, Christopher C. Thompson, MD, MSc, and colleagues report similar technical success rates for endoscopic ultrasound–guided gastroenterostomy (EUS-GE) and surgical gastrojejunostomy, despite more advanced cancer stage and worse performance status in the EUS-GE cohort.
Read More...
A study conducted by Daniel Dolan, MD, MPH, Scott J. Swanson, MD, of the Division of Thoracic Surgery, and colleagues determined that even at the Brigham’s high-volume center, low individual esophagectomy volume was associated with a higher perioperative complication rate.
Read More...
Researchers at Brigham and Women’s Hospital examined the two-year natural history of spinal metastases in cancer patients treated operatively or non-operatively and found that both types of treatment yielded improvements in health-related quality of life, but there was no survival advantage with surgery.
Read More...
Humsa Venkatesh, PhD, a cancer biologist, is studying the neural regulation of cancer and how nervous system cells found within the tumor microenvironment drive tumor growth. Her research has implications for primary brain tumors such as gliomas and for tumors that metastasize to the brain from other parts of the body.
Read More...
Adam S. Kibel, MD, and Jiun-Hung Geng, of the Brigham’s Division of Urology, and colleagues recently conducted the first study of how the combination of metabolic syndrome and its treatment affect response to androgen deprivation therapy in castration-sensitive prostate cancer.
Read More...
Researchers at Brigham and Women’s Hospital conducted the first study to compare the outcomes of different steroid dosing regimens prescribed for patients with high-grade ICI hepatitis. Stephen D. Zucker, MD, Shilpa Grover, MD, MPH, Michael Li, MD, MPH, and colleagues present evidence for starting with the lower dose.
Read More...
Using the world’s largest pharmacovigilance database, Eugene B. Cone, MD, Quoc-Dien Trinh, MD, and colleagues determined the risk of cardiac adverse events is increased substantially with abiraterone and not at all with enzalutamide.
Read More...
A retrospective study at the Brigham, led by Lisa Cooper, MD, and Laura N. Frain, MD, MPH, found that polypharmacy, potentially inappropriate medications, and frailty were not associated with complications after surgery for thoracic malignancies, but frailty was associated with increased length of hospital stay.
Read More...
Historically, stage 4 melanoma was considered incurable. In these cases, metastasectomy was performed for only as a palliative measure. But with recent advancements in systemic therapy, metastasectomy has emerged as an effective tool for extending the period of disease control and enhancing overall treatment response. Dana-Farber Brigham Cancer Center is at the forefront of this transformation.